MedPath

Comparison of Image Quality Between "Double Low Dose" Liver CT and Standard Liver CT

Not Applicable
Recruiting
Conditions
Metastasis to Liver
Colorectal Cancer
Registration Number
NCT05790590
Lead Sponsor
Seoul National University Hospital
Brief Summary

In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT) plays an important role in detecting carcinoma recurrence and assessing treatment response. In this study, we aim to investigate whether such a "double low" dose CT is feasible in patients with liver metastases of colorectal cancer using a vendor-agnostic artificial intelligence-based noise reduction and contrast enhancement software.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
176
Inclusion Criteria
  • colorectal cancer (CRC) patients
  • on surveillance or monitoring for liver metastasis (of CRC)
Exclusion Criteria
  • any relative or absolute contra-indication of CECT
  • diffuse infiltrative type of liver metastasis or on monitoring for too many liver lesions

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
lesion conspicuity on portal venous phase6 months after primary study completion.

qualitative analysis of lesion conspicuity on portal venous phase on five-point scale (higher score indicates better conspicuity).

Lesion conspicuity is compared between the two arms.

Secondary Outcome Measures
NameTimeMethod
Radiation dose1 month after primary study completion

Dose-length product (mGy\*cm) is compared between the two arms.

lesion conspicuity on arterial phase6 months after primary study completion.

qualitative analysis of lesion conspicuity on arterial phase on five-point scale (higher score indicates better conspicuity) Lesion conspicuity is compared between the two arms.

Contrast media (CM) dose1 month after primary study completion

The amount of CM dose is compared between the two arms.

lesion detectability12 months after primary study completion.

lesion detectability is compared between the two arms, compared with reference standard. Figure-of-merit was obtained.

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Hyuna Jung, RN
Contact
82-2-2072-4177
jha5375@snu.ac.kr
Jeong Min Lee, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.